Generalised anxiety disorder: Treatment options

Drugs

Volumn 62, Issue 11, 2002, Pages 1635-1648

  Sramek, John J ^a   Zarotsky, Victoria ^b   Cutler, Neal R ^a  

^a Ingenix Inc   (United States)

^b CALIFORNIA CLINICAL TRIALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CHLORDIAZEPOXIDE; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; GABAPENTIN; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; PLACEBO; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; TACHYKININ RECEPTOR ANTAGONIST; VENLAFAXINE;

ANXIETY NEUROSIS; DRUG EFFICACY; FATIGUE; HUMAN; LEARNING DISORDER; METHODOLOGY; PATIENT SELECTION; PSYCHOMOTOR DISORDER; PSYCHOTHERAPY; REVIEW; SEDATION; TREATMENT OUTCOME;

ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; BENZODIAZEPINES; BUSPIRONE; CLINICAL TRIALS; HUMANS; PSYCHOTHERAPY; RECEPTORS, CHOLECYSTOKININ;

EID: 0036327271     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262110-00005     Document Type: Review

References (103)

1. Generalized anxiety disorder: Nature and course
2. The clinical course and long-term management of generalized anxiety disorder
3. Behavioral side effects of benzodiazepines
4. Mixed anxiety and depression: Clinical implications
5. Comorbidity in a clinical sample of substance abuse
6. Stressful life events and the onset of generalized anxiety syndrome
7. Long term course of generalized anxiety
8. ECDEU assessment manual for psychopharmacology
9. A double-blind placebo controlled study comparing the efficacy and safety of ipsapirone versus lorazepam in patients with generalized anxiety disorder: A prospective multicenter trial
10. The safety and efficacy of ipsapirone vs lorazepam in outpatients with generalized anxiety disorder (GAD): Single site findings from a multicenter trial
11. Placebo response in anxiety disorders
12. Patient-provider relationships and the placebo effect
13. Early placebo response in anxious and depressed patients
14. Challenges in medication clinical trials
15. Adverse events in placebo treated patients with generalized anxiety disorder
16. Defining the maximum tolerated dose: Investigator, academic, industry and regulatory perspectives
17. Scientific and ethical concerns in clinical trials in Alzheimer's patients: The bridging study
18. Guidelines for conducting bridging studies in Alzheimer disease
19. Establishing the maximum tolerated dose of lesopitron in patients with generalized anxiety disorder (GAD): A bridging study
20. Differential sensitivity to the effects of psychotropic drugs: Psychotics vs normals: Asians vs Western populations
21. Acute effects of neuroloeptics on unmedicated schizophrenic patients and controls
22. Pharmacodynamics of antipsychotic drugs in schizophrenia
23. Safety and tolerability of CI-979 in patients with Alzheimer's disease
24. The safety and tolerance of xanomeline tartrate in patients with Alzheimer's disease
25. A multiple-dose safety trial of eptastigmine in Alzheimer's disease with pharmacodynamic observations of red blood cell cholinesterase
26. Benzodiazepine dependence: A review of the evidence
27. Opioid and benzodiazepine tolerance and dependence: Application of theory to critical care practice
28. Drug therapy: Current status of benzodiazepines
29. Current issues in benzodiazepine use for anxiety disorders
30. Current treatments of anxiety disorders in adults
31. Long-term diazepam therapy and clinical outcome
32. One-year follow-up of anxious patients treated with diazepam
33. Generalized anxiety disorder: New concepts and psychopharmacologic therapies
34. Relative abuse liability of diazepam and oxazepam: Behavioral and subjective dose effects
35. Effects of combined alcohol and benzodiazepine: A review
36. Mortality of patients dependent on benzodiazepines
37. Disinhibitory reactions to benzodiazepines: A review
38. Association of road-traffic accidents with benzodiazepine use
39. Benzodiazepine: Use, abuse and consequences
40. Adverse effects of benzodiazepines
41. Benzodiazepine side effects: Role of pharmacokinetics and pharmacodynamics
42. Benzodiazepine treatment of panic and agoraphobic symptoms: Use, dependence, toxicity, abuse
43. Long term use of benzodiazepines: Tolerance, dependence and clinical problems in anxiety and mood disorders
44. Benzodiazepine abuse in patients of doctors in domiciliary practice in the Basle area
45. Benzodiazepines withdrawal effects
46. Discontinuation reactions to alprazolam in panic disorder
47. Controlled discontinuation of benzodiazepine treatment for patients with panic disorder
48. Risks and benefits of long-term benzodiazepine use
49. Efficacy of buspirone in generalized anxiety disorder with coexsting mild depressive symptoms
50. Meta: Analysis of the safety and tolerability of two dose regimens of buspirone in patients with persistent anxiety
51. Efficacy and safety of two dosing regimens of buspirone in the treatment of outpatients with persistent anxiety
52. 1-(2-pyrimidinyl)-piperazine may alter the effects of the 5-HT1A agonist in the learned helplessness paradigm in rats
53. Comparison of the anticonflict effect of buspirone and its major metabolite 1-(2-pyrimidinyl)-piperazine (1-PP) in rats
54. Comparative behavioral profiles of buspitone and its metabolites 1-(2-pyrimidinyl)-piperazine (1-PP) in the murine elevated plus-maze
55. Buspirone, a novel nonbenzodiazepine anxiolytic
56. Treatment of anxiety with buspirone
57. The epidemiology of psychiatric comorbidity
58. Overview of antidepressants currently used to treat anxiety disorder
59. Imipramine and chlordiazepoxide in depressive and anxiety disorders II: Efficacy in anxious outpatients
60. Antidepressants for the treatment of generalized anxiety disorder: A placebo-controlled comparison of imipramine, trazodone, and diazepam
61. Paroxetine efficacy in the treatment of generalized anxiety disorder
62. Paroxetine in the treatment of generalized anxiety disorder: Results of a placebo-controlled flexible-dosage trial
63. A meta-analysis of the effects of venlafaxine on anxiety associated with depression
64. Double-blind, placebo controlled study of once daily venlafaxine XR in outpatients with generalized anxiety disorder (GAD)
65. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder
66. Venlafaxine XR is an efficacious short and long term treatment for generalized anxiety disorder
67. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial
68. The nonpharmacologic treatment of generalized anxiety disorder
69. Psychotherapy for generalized anxiety disorder
70. A controlled trial of treatments for generalized anxiety
71. A controlled comparison of cognitive-behavior therapy, diazepam and placebo in the management of generalized anxiety
72. A controlled comparison of cognitive-behavior therapy, diazepam and placebo alone and in combination for the treatment of generalized anxiety disorder
73. Benzodiazepines antagonize cholecystokinin-induced activation of rat hippocampal neurons
74. Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers: Preliminary findings
75. Enhances sensitivity to cholecystokinin tetrapeptide in panic disorder
76. A double blind placebo-controlled study of CCKB receptor antagonist CI-988, in patients with generalized anxiety disorder
77. A placebo-controlled trial of L-365,260, a CCKB receptor antagonist, in panic disorder
78. Single-site findings in a study of the safety and efficacy of a CCKB receptor antagonist CI-988, in the treatment of generalized anxiety disorder
79. Cholecystokinin potentiates dopamine inhibition of mesencephalic dopamine neurons in vitro
80. Cholecystokinin peptides, dopamine and schizophrenia: A review
81. CGP 49823, a novel NK-1 receptor antagonist: Behavioral effect
82. NKP608: A selective NK-1 receptor antagonist with anxiolytic-like effects in the social interaction and social exploration test in rats
83. Potential anxiolytic activity in gerbils from the substance P (SP receptor antagonist, CGP49823
84. The anxiolytic-like activity of GR159897, a non peptide NK-2 receptor antagonist, in rodent and primate models of anxiety
85. Distinct mechanism for antidepressant activity by blockade of central substance P receptors
86. F 11440, a potent, selective high efficacy 5-HT1A receptor agonist with marked anxiolytic and antidepressant potential
87. Clinical effects of the 5-HT1A partial agonists in depression: A composite analysis of buspirone in the treatment of depression
88. Comparison of the effects of the benzodiazepine midazolam and three serotonin antagonists on a consummatory conflict paradigm
89. Efficacy trial of the 5-ht2 antagonist MDL 11,939 in patients with generalized anxiety disorder
90. Placebo-controlled study of gabapentin treatment of panic disorder
91. The novel anticonvulsant drug, Gabapenitn (neurontin), binds to the α2δ subunit of a calcium channel
92. Pregabalin may represent a novel class of anxiolytic agents with a broad spectrum of activity
93. Zopiclone, the third generation hypnotic: A clinical overview
94. Pharmacological and clinical studies of cyclopyrrolones: Zopiclone and suriclone
95. Controlled comparison of the efficacy and safety of four doses of suriclone, diazepam, and placebo in generalized anxiety disorder
96. Synthesis and evaluation of analogues of the partial agnosit 6-(propyloxy)-4-(methoxymethyl)-beta-carboline-3-carboxylic acid ethyl ester (6-PBC) and the full agonist 6-(benzyloxy)-4-(methoxymethyl)-beta-carboline-3-carboxylic acid ethyl ester (ZK 93423) at wild type and recombinant GABAA receptors
97. High-affinity partial agonist imidazo[1,5,-a]quinoxaline amides, carbamate and ureas at the gamma-aminobutyric acid A/benzodiazepine receptor complex
98. Piperazine imidazo[1,5]quinoxaline ureas as high-affinity GABA A ligands of dual functionality